A number of research analysts recently issued reports on FENC shares. Stephens upgraded Fennec Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 18th.
Fennec Pharmaceuticals (FENC) reported its fourth-quarter 2024 earnings, surpassing expectations with an earnings per share (EPS) of -$0.06, better than the forecasted -$0.13. The company’s revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback